Title | SMPD1 mutations, activity, and α-synuclein accumulation in Parkinson's disease. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Alcalay, RN, Mallett, V, Vanderperre, B, Tavassoly, O, Dauvilliers, Y, Wu, RYJ, Ruskey, JA, Leblond, CS, Ambalavanan, A, Laurent, SB, Spiegelman, D, Dionne-Laporte, A, Liong, C, Levy, OA, Fahn, S, Waters, C, Kuo, S-H, Chung, WK, Ford, B, Marder, KS, Kang, UJung, Hassin-Baer, S, Greenbaum, L, Trempe, J-F, Wolf, P, Oliva, P, Zhang, XKate, Clark, LN, Langlois, M, Dion, PA, Fon, EA, Dupré, N, Rouleau, GA, Gan-Or, iv, Z |
Journal | Mov Disord |
Volume | 34 |
Issue | 4 |
Pagination | 526-535 |
Date Published | 2019 Apr |
ISSN | 1531-8257 |
Abstract | BACKGROUND: SMPD1 (acid-sphingomyelinase) variants have been associated with Parkinson's disease in recent studies. The objective of this study was to further investigate the role of SMPD1 mutations in PD.METHODS: SMPD1 was sequenced in 3 cohorts (Israel Ashkenazi Jewish cohort, Montreal/Montpellier, and New York), including 1592 PD patients and 975 controls. Additional data were available for 10,709 Ashkenazi Jewish controls. Acid-sphingomyelinase activity was measured by a mass spectrometry-based assay in the New York cohort. α-Synuclein levels were measured in vitro following CRISPR/Cas9-mediated knockout and siRNA knockdown of SMPD1 in HeLa and BE(2)-M17 cells. Lysosomal localization of acid-sphingomyelinase with different mutations was studied, and in silico analysis of their effect on acid-sphingomyelinase structure was performed.RESULTS: SMPD1 mutations were associated with PD in the Ashkenazi Jewish cohort, as 1.4% of PD patients carried the p.L302P or p.fsP330 mutation, compared with 0.37% in 10,709 Ashkenazi Jewish controls (OR, 3.7; 95%CI, 1.6-8.2; P = 0.0025). In the Montreal/Montpellier cohort, the p.A487V variant was nominally associated with PD (1.5% versus 0.14%; P = 0.0065, not significant after correction for multiple comparisons). Among PD patients, reduced acid-sphingomyelinase activity was associated with a 3.5- to 5.8-year earlier onset of PD in the lowest quartile versus the highest quartile of acid-sphingomyelinase activity (P = 0.01-0.001). We further demonstrated that SMPD1 knockout and knockdown resulted in increased α-synuclein levels in HeLa and BE(2)-M17 dopaminergic cells and that the p.L302P and p.fsP330 mutations impair the traffic of acid-sphingomyelinase to the lysosome.CONCLUSIONS: Our results support an association between SMPD1 variants, acid-sphingomyelinase activity, and PD. Furthermore, they suggest that reduced acid-sphingomyelinase activity may lead to α-synuclein accumulation. © 2019 International Parkinson and Movement Disorder Society. |
DOI | 10.1002/mds.27642 |
Alternate Journal | Mov. Disord. |
PubMed ID | 30788890 |
Grant List | / / Brookdale Foundation / / / Canadian Consortium om Neurodegeneration in Aging (CCNA) / / / Canadian Institutes of Health Research / / / Fonds de Recherche du Québec - Santé / / / Michael J. Fox Foundation for Parkinson's Research / K02NS080915 / / National Institutes of Health / UL1 TR000040 / / National Institutes of Health / / / Parkinson's Disease Foundation / K02 NS080915 / NS / NINDS NIH HHS / United States UL1 TR000040 / TR / NCATS NIH HHS / United States |